Live Breaking News & Updates on Sofinnova Investments Inc
Stay updated with breaking news from Sofinnova investments inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
03.08.2023 - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for second quarter 2023 and provided a business update. “Our goal is to continue to bring life-changing medicines to patients with rare disease. Use of LIVMARLI in Alagille . ....
Expands Mirum’s leadership in rare liver disease with two commercial products and a near-term Phase 3 label expansion opportunity
Advances Travere’s strategy to deliver new treatment standards from its pipeline of innovative medicines for rare diseases and strengthens financial foundation
Mirum to host conference call today, July 17, 2023, at 8:30 a.m. ET/5:30 a.m. PT ....
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) insider Kevin D. Bunker sold 80,000 shares of the company’s stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $30.02, for a total value of $2,401,600.00. Following the completion of the sale, the insider now owns 15,000 shares […] ....